Unraveling the metastatic niche in breast cancer bone metastasis through single-cell RNA sequencing
- PMID: 39066875
- DOI: 10.1007/s12094-024-03594-2
Unraveling the metastatic niche in breast cancer bone metastasis through single-cell RNA sequencing
Abstract
Purpose: Breast cancer (BRCA) is characterized by a unique metastatic pattern, often presenting with bone metastasis (BoM), posing significant clinical challenges. Through the study of the immune microenvironment in BRCA BoM offer perspectives for therapeutic interventions targeting this specific metastatic manifestation of BRCA.
Methods: This study employs single-cell RNA sequencing and TCGA data analysis to comprehensively compare primary tumors (PT), lymph node metastasis (LN), and BoM.
Results and conclusions: Our investigation identifies a metastatic niche in BoM marked by an increased abundance of cancer-associated fibroblasts (CAFs) and reduced immune cell presence. A distinct subtype (State 1) of BRCA BoM cells associated with adverse prognosis is identified. State 1, displaying heightened stemness traits, may represent an initiation phase for BoM in BRCA. Complex cell communications involving tumor, stromal, and immune cells are revealed. Interactions of FN1, SPP1, and MDK correlate with elevated immune cells in BoM. CD46, MDK, and PTN interactions drive myofibroblast activation and proliferation, contributing to tissue remodeling. Additionally, MDK, PTN, and FN1 interactions influence FAP+ CAF activation, impacting cell adhesion and migration in BoM. These insights deepen our understanding of the metastatic niche in breast cancer BoM.
Keywords: Bone metastasis; Breast cancer; Immune microenvironment; Myofibroblast-immune interactions; Single-cell RNA sequencing.
© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Conflict of interest statement
Declarations. Competing interests: The authors declare no conflict of interest. Ethical approval: This study was conducted in accordance with the Medical Ethics Committee of the Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Informed consent: All participants provided informed consent prior to their participation.
References
MeSH terms
Grants and funding
- No.82003805/National Natural Science Foundation of China
- No.82002776/National Natural Science Foundation of China
- No.2024A03J0649/Guangzhou Science and Technology Project
- No.201901D211471/Shanxi Province Science Foundation for Youths
- No.XSQ202101/Nanjing Military Region Medical Scientific and Technical Innovation Foundation Projects of People's Liberation Army of China
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous